Small-Molecule Inhibitors of Protein-Protein Interactions: Challenges and Prospects

Gene Family Targeted Molecular Design

Volumn , Issue , 2008, Pages 199-233

  Whitty, Adrian ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

"drug like" chemical space constraints; New PPI targets and druggability assessment; Protein protein interaction small molecule inhibitors

Indexed keywords

EID: 84889278844     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470423936.ch7     Document Type: Chapter

References (113)

1. An J, Totrov M, Abagyan R, 2004. Comprehensive identification of ''druggable'' protein ligand binding sites. Genome Inform. 15:31.
2. Ansari S, Helms V, 2005. Statistical analysis of predominantly transient protein-protein interfaces. Proteins 61:344.
3. Arkin M, Lear JD, 2001. A new data analysis method to determine binding constants of small molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. Anal. Biochem. 299:98.
4. Arkin MR, Wells JA, 2004. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3:301.
5. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS, Wells JA, Braisted AC, 2003. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl. Acad. Sci. USA 100:1603.
6. Babaoglu K, Shoichet BK, 2006. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2:720.
7. Bahadur RP, Chakrabarti P, Rodier F, Janin J, 2004. A dissection of specific and non-specific protein-protein interfaces. J. Mol. Biol. 336:943.
8. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W, 1993. Crystal structure of the soluble human 55 Kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431.
9. Bernat B, Sun M, Dwyer M, Feldkamp M, Kossiakoff AA, 2004. Dissecting the binding energy epitope of a high-affinity variant of human growth hormone: cooperative and additive effects from combining mutations from independently selected phage display mutagenesis libraries. Biochemistry 43:6076.
10. Boehm HJ, Boehringer M, Bur D, Gmuender H, Huber W, Klaus W, Kostrewa D, Kuehne H, Luebbers T, Meunier-Keller N, Mueller F, 2000. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 43:2664.
11. Bogan A, Thorn KS, 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280:1.
12. Bork P, Jensen LJ, von Mering C, Ramani AK, Lee I, Marcotte EM, 2004. Protein interaction networks from yeast to human. Curr Opin. Struct. Biol. 14:292.
13. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, Yu C, Arkin MR, Raimundo BC, 2003. Discovery of a potent small molecule IL-2 inhibitor through fragment. JACS 125:3714.
14. Brown SP, Hajduk PJ, 2006. Effects of conformational dynamics on predicted protein druggability. Chem. Med. Chem. 1:70.
15. Carr RA, Congreve M, Murray CW, Rees DC, 2005. Fragment-based lead discovery: leads by design. Drug Discov. Today 10:987.
16. Chakrabarti P, Janin J, 2002. Dissecting protein-protein recognition sites. Proteins 47:334.
17. Chatzantoni K, Moutzaki A, 2006. Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr Top. Med. Chem. 6:1707.
18. Clackson T, Ultsch MH, Wells JA, de Vos AM, 1998. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J. Mol. Biol. 277:1111.
19. Cochran AG, 2000. Antagonists of protein-protein interactions. Chem. Biol. 7:R85.
20. Dalvit C, Caronni D, Mongelli N, Veronesi M, Vulpetti A, 2006. NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. Curr Drug Discov. Technol. 3:115.
21. Davis JM, Tsou LK, Hamilton AD, 2007. Synthetic non-peptide mimetics of alpha-helices. Chem. Soc. Rev. 36:326.
22. Davis MD, Teague SJ, 1999. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Chem. Int. Ed. Engl. 38:736.
23. DeLano WL, 2002. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin. Struct. Biol. 12:14.
24. Driggers EM, Hale SP, Lee J, Terrett NK, 2008. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat. Rev. Drug Discov. 7:608.
25. Dudkina AS, Lindsley CW, 2007. Small molecule protein-protein inhibitors for the p53-MDM2 interaction. Curr. Top. Med. Chem. 7:952.
26. Emerson SD, Palermo R, Liu CM, Tilley JW, Chen L, Danho W, Madison VS, Greeley DN, Ju G, Fry DC, 2003. NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction. Protein Sci. 12:811.
27. Erlanson DA, 2006. Fragment-based lead discovery: a chemical update. Curr. Opin. Bio-technol. 17:643.
28. Eyrisch S, Helms V, 2007. Transient pockets on protein surfaces involved in protein-protein interaction. J. Med. Chem. 50:34-57.
29. Fear G, Komarnytsky S, Raskin I, 2007. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol. Ther. 113:354.
30. Fellouse FA, Wiesmann C, Sidhu SS, 2004. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc. Natl. Acad. Sci. USA 101:12467.
31. Fellouse FA, Barthelemy PA, Kelley RF, Sidhu SS, 2006. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J. Mol. Biol. 357:100.
32. Feng BY, Simeonov A, Jadhav A, Babaoglu K, Inglese J, Shoichet BK, Austin CP, 2007. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50:2385.
33. Fletcher S, Hamilton AD, 2007. Protein-protein interaction inhibitors: small molecules from screening techniques. Curr. Top. Med. Chem. 7:922.
34. Glaser F, Steinberg DM, Vakser IA, Ben-Tal N, 2001. Residue frequencies and pairing preferences at protein-protein interfaces. Proteins 43:89.
35. Glaser F, Morris RJ, Najmanovich RJ, Laskowski RA, Thornton JM, 2006. A method for localizing ligand binding pockets in protein structures. Proteins 62:479.
36. Groner B, Hartmann C, Wels W, 2004. Therapeutic antibodies. Curr. Mol. Med. 4:539.
37. Hajduk PJ, 2006. Fragment-based drug design: how big is too big? J. Med. Chem. 49:69-72.
38. Hajduk PJ, Greer J, 2007. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6:211.
39. Hajduk PJ, Bures M, Praestgaard J, Fesik SW, 2000. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 43:3443.
40. Hajduk PJ, Huth JR, Fesik SW, 2005a. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48:2518.
41. Hajduk PJ, Huth JR, Tse C, 2005b. Predicting protein druggability. Drug Discov. Today 10:16-75.
42. Hale G, 2006. Therapeutic antibodies-delivering the promise? Adv. Drug Deliv. Rev. 58:633.
43. Hann MM, Leach AR, Harper G, 2001. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41:856.
44. He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, Fung AD, Farrington G, Eldredge JK, Day ES, Cruz LA, Cachero TG, Miller SK, Friedman JE, Choong IC, Cunningham BC, 2005. Small-molecule inhibition of TNF-alpha. Science 310:10-22.
45. Headd JJ, Ban YE, Brown P, Edelsbrunner H, Vaidya M, Rudolph J, 2007. Protein-protein interfaces: properties, preferences, and projections. J. Proteome Res. 6:25-76.
46. Hilser VJ, Dowdy D, Oas TG, Freire E, 1998. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc. Natl. Acad. Sci. USA 95:9903.
47. Hopkins AL, Groom CR, 2002. The druggable genome. Nat. Rev. Drug Discov. 1:727.
48. Hopkins AL, Groom CR, Alex A, 2004. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9:430.
49. Humphries MJ, 1992. Peptide recognition motifs involved in the binding of integrins to their ligands. Kidney Int. 41:645.
50. Humphris EL, Kortemme T, 2007. Design of multi-specificity in protein interfaces. PLoS Comput. Biol. 3:e164.
51. Huntington JA, Read RJ, Carrell RW, 2000. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923.
52. Huth JR, Mendoza R, Olejniczak ET, Johnson RW, Cothron DA, Liu Y, Lerner CG, Chen J, Hajduk PJ, 2005. Alarm NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens JACS 127:217.
53. Imming P, Sinning C, Meyer A, 2006. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5:821.
54. Jain R, Ernst JT, Kutzki O, Park HS, Hamilton AD, 2004. Protein recognition using synthetic surface-targeted agents. Mol. Divers. 8:89.
55. Janin J, 1999. Wet and dry interfaces: the role of solvent in protein-protein and protein-DNA recognition. Structure 7:R277.
56. Janin J, Miller S, Chothia C, 1988. Surface, subunit interfaces and interior of oligomeric proteins. J. Mol. Biol. 204:155.
57. Jencks WP, 1975. Binding energy, specificity, and enzymic catalysis: the circe effect. Adv. Enzymol. Relat. Areas Mol. Biol. 43:219.
58. Jiang S, Tovchigrechko A, Vakser IA, 2003. The role of geometric complementarity in secondary structure packing: a systematic docking study. Protein Sci. 12:16-46.
59. Johnson-Leger C, Power CA, Shomade G, Shaw JP, Proudfoot AE, 2006. Protein therapeutics-lessons learned and a view of the future. Expert Opin. Biol. Ther. 6:1.
60. Jones S, Thornton JM, 1996. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. USA 93:13.
61. Jordan MA, 2002. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2:1.
62. Keller TH, Pichota A, Yin Z, 2006. A practical view of 'druggability.' Curr. Opin. Chem. Biol. 10:357.
63. Keskin O, Ma B, Nussinov R, 2005. Hot regions in protein-protein interactions: the organization and contribution of structurally conserved hot spot residues. J. Mol. Biol. 345:12-81.
64. Kortemme T, Kim DE, Baker D, 2004. Computational alanine scanning of protein-protein interfaces. Sci. STKE p12.
65. Lipinski CA, 2000. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44:235.
66. Lo Conte L, Chothia C, Janin J, 1999. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285:21-77.
67. Macarron R, 2006. Critical review of the role of HTS in drug. Drug Discov. Today 11:277.
68. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR, 2003. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8:212.
69. McGovern SL, Helfand BT, Feng B, Shoichet BK, 2003. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46:42-65.
70. Milroy LG, Zinzalla G, Prencipe G, Michel P, Ley SV, Gunaratnam M, Beltran M, Neidle S, 2007. Chemical variation of natural-product-like scaffolds: design, synthesis, and biological activity of fused bicyclic acetal derivatives. Angew. Chem. Int. Ed. Engl. 46:24-93.
71. Mintz S, Shulman-Peleg A, Wolfson HJ, Nussinov R, 2005. Generation and analysis of a protein-protein interface data set with similar chemical and spatial patterns of interactions. Proteins 61:6.
72. Moriera, IS, Fernandez PA, Ramos MJ, 2006. Computational alanine scanning mutagenesis-an improved methodological approach. J. Comput. Chem. 28:644.
73. Moriera IS, Fernandez PA, Ramos MJ, 2007. Unraveling hot spots: a comprehensive computational mutagenesis study. Theor. Chem. Acc. 117:99.
74. Mousa SA, Goncharuk O, Miller D, 2007. Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin. Biol. Ther. 7:617.
75. Moza B, Buonpane RA, Zhu P, Herfst CA, Rahman AK, McCormick JK, Kranz DM, Sundberg EJ, 2006. Long-range cooperative binding effects in a T-cell receptor variable domain. Proc. Natl. Acad. Sci. USA 103:9867.
76. Nayal M, Honig B, 2006. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. Proteins 63:892.
77. Newman DJ, Cragg GM, 2007. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70:461.
78. Niederhauser O, Mangold M, Schubenel R, Kusznir EA, Schmidt D, Hertel C, 2000. NGF ligand alters NGF signaling via p75(NTR) and TrkA. J. Neurosci. Res. 61:263.
79. Nooren IM, Thornton JM, 2003. Structural characterisation and functional significance of transient protein-protein interactions. J. Mol. Biol. 325:991.
80. Ofran Y, Rost B, 2003. Analysing six types of protein-protein interfaces. J. Mol. Biol. 325:377.
81. Ohtsuka M, Konno F, Honda H, Oikawa T, Ishikawa M, Iwase N, Isomae K, Ishii F, Hemmi H, Sato S, 2002. Ppa250 [3-(2,4-difluorophenyl)-6-[2-[4-(1H-imidazol-1-ylmethyl) phenoxy] ethoxy]-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis. J. Pharmacol. Exp. Ther. 303:52.
82. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, 2005. An inhibitor of bcl-2 family proteins induces regression of solid tumours. Nature 435:677.
83. Ottiger M, Zerbe O, Guntert P, Wuthrich K, 1997. The NMR solution conformation of unligated human cyclophilin A. J. Mol. Biol. 272:64.
84. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL, 2003. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2:736.
85. Pawson T, Nash P, 2000. Protein-protein interactions define specificity in signal transduction. Genes Dev. 14:10-27.
86. Pawson T, Nash P, 2003. Assembly of cell regulatory systems through protein interaction domains. Science 300:445.
87. Pawson T, Gish GD, Nash P, 2001. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol. 11:504.
88. Reayi A, Arya P, 2005. Natural product-like chemical space: search for chemical dissectors of macromolecular interactions. Curr. Opin. Chem. Biol. 9:240.
89. Rees DC, Congreve M, Murray CW, Carr R, 2004. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3:660.
90. Reichmann D, Rahat O, Albeck S, Meged R, Dym O, Schreiber G, 2005. The modular architecture of protein-protein binding interfaces. Proc. Natl. Acad. Sci. USA 102:57.
91. Rodier F, Bahadur RP, Chakrabarti P, Janin J, 2005. Hydration of protein-protein interfaces. Proteins 60:36.
92. Sandborn WJ, 2007. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev. Gastroenterol. Disord. 7:S2-S23.
93. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW, 1997. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983.
94. Schreiber SL, 2000. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964.
95. Schreiber SL, Crabtree GR, 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13:136.
96. Schuffenhauer A, Ruedisser S, Marzinzik AL, Jahnke W, Blommers M, Selzer P, Jacoby E, 2005. Library design for fragment based screening. Curr. Top. Med. Chem. 5:751.
97. Schuffenhauer A, Brown N, Selzer P, Ertl P, Jacoby E, 2006. Relationships between molecular complexity, biological activity, and structural diversity. J. Chem. Inf. Model 46:525.
98. Scott JK, Huang SF, Gangadhar BP, Samoriski GM, Clapp P, Gross RA, Taussig R, Smrcka AV, 2001. Evidence that a protein-protein interaction 'hot spot' on heterotrimeric G protein betagamma subunits is used for recognition of a subclass of effectors. EMBO J. 20:767.
99. Shimoaka M, Springer TA, 2003. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2:703.
100. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW, 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:15-31.
101. Tilley J, Chen L, Fry D, Emerson S, Powers G, Biondi D, Varnell T, Trilles R, Guthrie R, Mennona F, Kaplan G, LeMahieu R, Carson M, Han R-J, Liu C-M, Palermo R, Ju G, 1997. Identification of a small molecule inhibitor of the IL-2/IL-2Ralpha receptor interaction which binds to IL-2. JACS 119:7589.
102. Toogood PL, 2002. Inhibition of protein-protein association by small molecules: approaches and progress. J. Med. Chem. 45:15-43.
103. Tsai CJ, Lin SL, Wolfson HJ, Nussinov R, 1997. Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci 6:53.
104. Tyndall JD, Fairlie DP, 1999. Conformational homogeneity in molecular recognition by proteolytic enzymes. J. Mol. Recognit. 12:363.
105. Uvebrant K, da Graca Thrige D, Rosen A, Akesson M, Berg H, Walse B, Bjork P, 2007. Discovery of selective small-molecule CD80 inhibitors. J. Biomol. Screen 12:464.
106. Vakser IA, Aflalo C, 1994. Hydrophobic docking: a proposed enhancement to molecular recognition techniques. Proteins 20:320.
107. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD, 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2615.
108. Waal ND, Yang W, Oslob JD, Arkin MR, Hyde J, Lu W, McDowell RS, Yu CH, Raimundo BC, 2005. Identification of nonpeptidic small-molecule inhibitors of interleukin-2. Bioorg. Med. Chem. Lett. 15:983.
109. Weisel M, Proschak E, Schneider G, 2007. Pocketpicker: analysis of ligand binding-sites with shape descriptors. Chem. Cent. J. 1:7.
110. Wells JA, 1996. Binding in the growth hormone receptor complex. Proc. Natl. Acad. Sci. USA 93:1.
111. Whitty A, Kumaravel G, 2006. Between a rock and a hard place? Nat. Chem. Biol. 2:112.
112. Yan C, Wu F, Jernigan RL, Dobbs D, Honavar V, 2008. Characterization of protein-protein interfaces. Protein J. 27:59.
113. Young L, Jernigan RL, Covell DG, 1994. A role for surface hydrophobicity in protein-protein recognition. Protein Sci. 3:717.